Glucophage Xr

Glucophage XR is an extended‑release tablet that contains the active ingredient metformin hydrochloride. Marketed in the European Union, this prescription‑only medication belongs to the biguanide class of oral antidiabetic agents. It is formulated to release metformin gradually after oral administration, helping to lower blood glucose levels in adults with type 2 diabetes mellitus. The product does not contain a specified strength in this summary. It is intended for use under supervision.

Glucophage XR is indicated for the management of type 2 diabetes mellitus in adults.

- As an adjunct to diet and exercise to improve glycemic control. - In combination with other oral antidiabetic agents when monotherapy is insufficient. - For patients who benefit from once‑daily dosing due to the extended‑release formulation. - To reduce hepatic glucose production and increase peripheral insulin sensitivity. - For patients with stable renal function where metformin is appropriate. - To help maintain target HbA1c levels as part of a comprehensive diabetes plan.

The safety profile of Glucophage XR includes both common and less frequent adverse reactions that may occur during treatment.

Common: - Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea. - Metallic taste in the mouth. - Decreased appetite. - Mild headache.

Serious: - Lactic acidosis, a rare but potentially life‑threatening condition. - Severe skin reactions such as Stevens‑Johnson syndrome. - Significant vitamin B12 deficiency with long‑term use.

Before prescribing Glucophage XR, clinicians should evaluate several precautionary factors to ensure safe use.

- Assess renal function; metformin is contraindicated in severe renal impairment. - Review hepatic function, as liver disease may increase risk of lactic acidosis. - Consider age; older adults may have altered drug clearance. - Evaluate for conditions that predispose to hypoxia, such as heart failure or recent myocardial infarction. - Monitor vitamin B12 levels during prolonged therapy. - Avoid use in patients with a history of alcohol abuse.

Glucophage XR can interact with other medicines, affecting its efficacy or safety profile.

Avoid: - Concurrent use with iodinated contrast agents without appropriate discontinuation. - Co‑administration with other biguanides. - Use with drugs that may impair renal function, such as NSAIDs, may increase risk.

Use with caution: - Combination with sulfonylureas may increase risk of hypoglycemia. - Concomitant use of diuretics may affect renal clearance. - Alcohol intake can potentiate lactic acidosis risk. - Thyroid hormones may alter glucose metabolism.